As such, the inhibitory effect of p17 on Src-mediated TKs5 phosphorylation highlights its potential as a key regulator in reducing cancer cell motility, providing insights into its therapeutic implications in the suppression of cancer metastasis. Here, SH3PXD2A is linked to cancer.